Kornimate/medical-research-clean huggingface dataset:
spray cryotherapy for the management of benign central airway stenosis (cryo-bas)

Conditions: Stenosis of Trachea

Summary: the goal of this clinical trial is to compare spray cryotherapy plus balloon dilatation versus current standard of care (soc - steroid injection, radial cuts and balloon dilatation) in patients with benign airway stenosis with simple stenosis. the main question\[s\] investigators aim to answer are: 1. what is the need for reintervention and time to reintervention in participants with benign airway stenosis with simple stenosis who receive spray cryotherapy plus balloon dilatation versus standard of care alone? 2. to evaluate patient experience, physiological, anatomical changes, health care utilization and safety of the sct plus balloon dilatation versus standard of care alone. researchers will compare spray cryotherapy plus balloon dilatation versus current standard of care (soc - steroid injection, radial cuts and balloon dilatation) in patients with benign airway stenosis with simple stenosis to see if it reduces the need of re intervention. participants will surgery and receive one of the two interventions.

investigators propose a single center, single-blinded (patient), randomized 1:1 trial comparing sct plus balloon dilatation (experimental group) vs soc alone (control group). investigators aim to recruit 50 patients. study will span 2-year duration with 1 year recruitment. follow up at 6 weeks, 3 months, 6 months, 12 months. the patient's airway will be either a laryngeal mask airway or a rigid bronchoscopy for passive venting and gas egress.

Eligibility criteria:
inclusion criteria: * 1. patients with symptomatic, benign, simple stenosis of the trachea and/or subglottic space. * 2. stenotic airway of diameter \< 1cm. exclusion criteria: 1. complex stenosis, cartilage involvement (malacia or fracture). 2. patients with giant bullae (\> a third of hemithorax) or bullae \>3cm. 3. concurrent tracheoesophageal fistula, active tracheal malignancy. 4. presence of concomitant upper airway obstruction. 5. pregnancy

Keywords: stenosis of trachea benign spray cryotherapy
bacterial vaginosis screening and treatment to reduce infective complications, abortion and preterm delivery

Conditions: Vaginosis, Bacterial; Abortion, Spontaneous; Premature Birth

Summary: to determine whether screening of pregnant women with history of previous preterm delivery or with premature contractions for bacterial vaginosis using vs-sense, and treatment of positive women will reduce the risk of spontaneous preterm birth.

this is an open-label, comparative, and prospective study. pregnant women, pregnancy week 26 to 36+6, between the ages 18-45, who were hospitalized in the high risk department, with history of previous preterm delivery and/or with premature contractions. patient with premature ruptured membrane will be excluded. in the hospital pregnant women with history of previous preterm delivery or with premature contractions, (participants) will be examined by speculum with no lubricant, the clinician will use the vs-sense to sample vaginal secretions and will immediately observe and record the color obtained.should the vs-sense produce positive results the physician will consider giving clindamycin treatment.

Eligibility criteria:
inclusion criteria: * pregnant subjects, aged 18-45 years, pregnancy week 26 to 36+6, with history of previous preterm delivery or with premature contractions. exclusion criteria: * subject with ruptured membranes. * subject with signs and symptoms of pelvic inflammatory disease. * subject who has used vaginal douching within 12 hours prior to arrival at the hospital. * subject who has applied local antiseptic, antibiotic or vaginal treatment within the previous 3 days. * subjects who have had sexual intercourse within the last 12 hours. * subject with blood in her vaginal secretions. * subject is currently participating in another clinical study that may directly or indirectly affect the results of this study. * subject is unable or unwilling to cooperate with study procedures.

Keywords: vaginosis, bacterial abortion, spontaneous premature birth
research on the mechanisms of treatment non-response in inflammatory bowel disease based on multi-omics technology

Conditions: Inflammatory Bowel Diseases

Summary: in recent years, biologic agents such as infliximab, vedolizumab, and ustekinumab have demonstrated tremendous potential in the treatment of inflammatory bowel disease (ibd), altering the traditional treatment paradigm for ibd. despite their significant efficacy, there remains a subset of patients who do not respond to biologic agents, necessitating research into the response mechanisms of biologic therapy to explore more precise treatment strategies. preliminary work by the principal investigator has identified multiple potential responder cell subtypes to biologic agents, which may be influenced by the gut and oral microbiota. therefore, this project proposes to investigate the mechanisms of response to biologic agents, aiming to explore more precise treatment strategies, through the integration of single-cell transcriptomics, 16s rrna, and other multi-omics technologies on tissue samples, feces, saliva, peripheral blood, etc., from ibd patients before and after treatment. this will involve integrating bioinformatics analysis and in vitro/in vivo functional validation to elucidate the roles of treatment-responsive cell subtypes and gut and oral microbiota in the inflammatory microenvironment of the intestine, with the aim of uncovering the mechanisms of biologic agent therapy and providing new clues for the development of next-generation drug targets.


Eligibility criteria:
inclusion criteria: * patients aged 18 years or older; diagnosed with inflammatory bowel disease according to the 2019 european ecco-esgar guidelines; who have not previously received any biologic therapy or, based on the treating physician's judgment, require treatment with infliximab (ifx), adalimumab (ada), vedolizumab (vdz), or ustekinumab (ust) after 3 months of medication. exclusion criteria: * patients who refuse treatment with infliximab, adalimumab, vedolizumab, or ustekinumab for various reasons, or those with contraindications; patients currently using antibiotics or who have been in contact with probiotics/antibiotics in the past month; those with concomitant active autoimmune diseases, active tumors, etc.; those with severe oral diseases; patients experiencing other diseases unrelated to inflammatory bowel disease during treatment but may affect the efficacy of inflammatory bowel disease treatment; pregnant or lactating women; those deemed unsuitable for participation in this study by the investigator's judgment.
collecting and storing samples of blood and tumor tissue from patients with osteosarcoma

Conditions: Osteosarcoma

Summary: the purpose of this study is to collect and store samples of blood and tumor tissue from patients with osteosarcoma. collecting and storing samples of tumor tissue and blood from patients to test in the laboratory may help the study of cancer in the future.

objectives: i. to collect biological specimens from patients with osteosarcoma at children?s oncology group (cog) institutions. ii. to provide a repository for long-term storage of osteosarcoma-related biological materials. iii. to make these specimens available to qualified researchers to understand the biology of osteosarcoma and correlate these results with the patients' clinical data. outline: after the initial submission of blood samples, patients may undergo open or closed biopsy in order to obtain fresh and frozen tissue samples as well as paraffin embedded material. patients who are enrolled at the time of initial diagnosis but then have a definitive surgery or develop recurrent disease may submit additional samples (paraffin block, frozen and fresh tumor tissue, or slides together with blood samples). autopsy tumor samples may also be submitted.

Eligibility criteria:
inclusion criteria: * all osteosarcoma patients seen at cog institutions are eligible, including the following: * newly diagnosed patients * patients with recurrent disease who were not enrolled at the time of diagnosis * the following specimens from the initial biopsy (and/or definitive surgery if an up-front resection is performed) are required: * paraffin embedded block or 30 unstained slides * pretreatment blood consisting of 5 ml serum, 10 ml plasma, and 10 ml heparinized whole blood * fresh and frozen tumor specimens * patients are not required to enter a therapeutic study to enroll on this study
ultrasound and electrophysiology study of hand in systemic sclerosis patients and contributors of hand dysfunction

Conditions: Scleroderma; Hand Functionality; Quality of Life (QOL)

Summary: the goal of this research is to assess quality of life and hand function in systemic sclerosis patients via specific questionnaires, and to determine the main contributors to hand dysfunction via a thorough hand ultrasound study and electrophysiology study.

systemic sclerosis (ssc) is a rare multiorgan autoimmune disease characterized by vasculopathy and fibrosis. its prevalence rates vary greatly by geographic area from 9.3 to 660 per million. the disease is primarily observed in individuals aged 35 to 55 years, with females being four to six times more affected than males. hand involvement is an early manifestation of systemic ssc. it's recognized as a major driver of disability and diminished quality of life . managing hand pain can be particularly challenging due to the coexistence of non-inflammatory arthralgia, inflammatory arthritis, acro-osteolysis, tenosynovitis, joint contractures, tendon friction rubs, nerve entrapment, raynaud's phenomenon, digital ulcers, sclerodactyly, calcinosis and chronic pain. due to the multifactorial etiology of hand functional disability in ssc, it is important to define the contribution of each factor or structure to this issue. this understanding is essential for developing a rehabilitation and medical treatment oriented approach to disease management. while physical examination and radiographs are the first line methods for evaluating hand pain, they are limited in scope and miss many underlying etiologies of hand impairment. musculoskeletal ultrasound (msus) is rapidly becoming a mainstay diagnostic tool in the assessment of rheumatic diseases due to its low cost, portability, and safety as a non-ionizing imaging modality. the outcome measures in rheumatology (omeract) ultrasound working group has provided definitions for pathologic lesions seen in rheumatic disorders, which offers a valuable framework for the assessment of hand impairment in ssc.

Eligibility criteria:
inclusion criteria: adult ssc patients ( \>18 yrs ) who are fulfilling the the eular/acr 2013 classification criteria exclusion criteria: 1. individuals with other autoimmune diseases (systemic lupus, sjogren syndrome, rheumatoid arthritis dermatomyositis, mixed connective tissue disease). 2. usage of drugs that can cause peripheral neuropathy and chronic alcohol abuse history. 3. presence of diabetes mellitus, thyroid dysfunction and renal failure

Keywords: hand dysfunction musculoskeletal ultrasound electrophysiology quality of life scleroderma
the effects of simulated competition on repeated-sprint cycling performance

Conditions: Stress

Summary: sprint cycling performance has been found to be reduced when two sprints were undertaken 12 minutes apart. in a follow-up study, the investigators found evidence to suggest that some of the loss in performance that was experienced in the second sprint was due to a psychological, rather than a physiological, limitation. it is conceivable that this loss in performance would not exist during a competition. the aim of this study is, therefore, to investigate the influence that a competitive environment has on repeated-sprint performance.


Eligibility criteria:
inclusion criteria: * regular strength/sprint training (at least 2 sessions per week) exclusion criteria: * injured or a contraindicative medical condition
augment® bone graft (formerly gem os™1 bone graft) compared to autologous bone graft in foot and ankle fusions

Conditions: Foot Fusion

Summary: study objectives: demonstrate equivalent clinical and radiologic outcomes to the "gold standard" (abg) in a representative clinical model (hindfoot and ankle fusions) study hypothesis: augment® bone graft is an equivalent bone grafting substitute to autologous bone graft in applications as shown by non-inferiority analysis study rationale: evaluate a fully synthetic growth-factor enhanced bone graft substitute to facilitate fusion in conditions or injuries requiring bone graft in a representative clinical fusion model and thus the opportunity to provide equivalent union rates as abg without necessitating an additional invasive procedure to harvest the graft regulatory phase: investigational device exemption (ide) for premarket approval (pma) application as a bone regeneration system, pivotal phase


Eligibility criteria:
inclusion criteria: 1) bone defect in the hindfoot or ankle requiring fusion using open surgical technique with supplemental bone graft/substitute, requiring one of the following procedures: * ankle joint fusion * subtalar fusion * calcaneocuboid fusion * talonavicular fusion * triple arthrodesis (subtalar, talonavicular and calcaneocuboid joints) * double fusions (talonavicular and calcaneocuboid joints) exclusion criteria: 1. previous fusion surgery of the proposed fusion site. 2. the patient uses chronic medications known to affect the skeleton (e.g. glucocorticoid usage \> 10mg/day). 3. pregnant or a female intending to become pregnant during this study period. 4. morbidly obese (bmi \> 45 kg/m2)

Keywords: arthritis ankle pain foot pain hindfoot fracture ankle fracture
severity of rsv infections in twins

Conditions: RSV Infection; Bronchiolitis

Summary: respiratory syncytial virus (rsv) infection is the most common cause of severe lower respiratory tract infection (lrti) in the pediatric population worldwide. age at the time of infection, prematurity, multiparity, exposure to smoke and the level of passive immunity transmitted at birth are the main risk factors for lower respiratory infection associated with rsv. other factors, including the innate immune response, respiratory microbiota, and intra-host viral heterogeneity, may also affect outcomes but are not fully considered in rsv infection. exploring the impact of these factors is difficult due to the heterogeneity of the population which makes statistical adjustment difficult. thus, twin models are useful in understanding the impact of the host on the environment, as twins often share similar exposure to infection and many risk factors, but not all are ie different prenatal and postnatal conditions, differential transfer of maternal antibodies and the genetic makeup of heterozygotes.


Eligibility criteria:
inclusion criteria: * twins born at hospices civils de lyon in the years 2012 to 2020 * at least one twin hospitalized with positive rsv-pcr during the first year of life exclusion criteria: * major differential underlying disease between twins * death of a twin before the rsv epidemic period of the first year of life * nosocomial infection * lack of understanding of the study or questionnaire by parents * lack of parental consent

Keywords: rsv infections in twins bronchiolitis very-severe-lrti severe-lrti lrti upper respiratory tract infection rsv infection human infant
comparison of triple antibiotic paste with combination of chitosan and calcium hydroxide as a root canal disinfectant

Conditions: Periapical Abscess

Summary: investigators observed the clinical and radiographic healing of periapical lesion using chitosan mixed with calcium hydroxide and compared it with triple antibiotic paste when used as intracanal medicament in 3months, 6 months and 12 months.

aim: to evaluate and compare the healing of periapical lesions using chitosan mixed with calcium hydroxide or triple antibiotic paste at 3,6 and 12 months. methodology: 20 adult patients having periapical lesions in single rooted teeth were selected in this study after being assessed using the pai index. patients were randomly assigned to: group - i (n=10) chitosan with ca (oh)2 and group -ii (n=10) triple antibiotic paste (tap) after access opening and cleaning and shaping were done in the first visit, the pertinent intracanal medicaments were placed depending on the patient group. after 4 weeks, on the second visit, the medicament was removed andobturation was done in the asymptomatic teeth. both clinical and radiographic endodontic evaluation was done at 0, 3, 6 and 12months using the same parameters. radiographic evaluation was done using the pai index and was compared at 0, 3, 6, and 12 months after treatment, z test.

Eligibility criteria:
inclusion criteria: * patients aged between 18 and 40 years periapical lesion (not more than 5mm) radiographically.on single rooted teeth * roots with closed apex. * systemically healthy patients. exclusion criteria:all patients who respond positive to allergic patch test \[triple antibiotic paste\] and drugs. * teeth with previous endodontic therapy performed. * patients with a history of any systemic diseases. * pregnant and lactating women. * tooth associated with vertical root fracture and coronal perforation. * tooth affected with calcific degeneration. * presence of external or internal root resorption. * blunderbuss apex.
brain tumor treatment satisfaction survey

Conditions: Brain Tumors

Summary: patients with recent diagnosis and treatment of a brain tumor will complete a short questionnaire concerning the patient's quality of life and emotional state since receiving treatment. caregivers will complete a one-page questionnaire concerning the patient's quality of life and emotional state since receiving treatment.

patients with a recent diagnosis and treatment of a brain tumor (primary or metastatic; n=105, 61% female, 39% male) were identified in the clinics of semmes-murphey neurologic and spine institute or the methodist university hospital in memphis, tn. caregivers were recruited from among relatives and friends who provide the most day-to-day care to the patient. all participants were between 3 months and 1 year from their most recent brain tumor treatment. participants were given a simple, 5-point based survey to asses treatment-specific satisfaction, patient education, posttreatment quality of life, and pre- and post-treatment emotional impact. therapeutic modalities surveyed include: surgery, external beam radiotherapy, whole-brain radiotherapy, stereotactic radiosurgery, and chemotherapy.

Eligibility criteria:
inclusion criteria: * patients who are between 3 months and one year out from treatment for their brain tumor * karnofsky performance status (kps) \>= 60 * age 18 years or over, any gender, any race * "patient caregivers will be individuals who provide the most day-to-day care for their respective brain tumor patients exclusion criteria: * no exclusions

Keywords: brain tumors survey
reveal the patterns of presentation, management and outcome of patients with sclc and stage iii nsclc in saudi arabia:

Conditions: Lung Cancer

Summary: a retrospective, multi-centre, observational study to describe the treatment patterns, the demographic, clinical outcomes, treatment effectiveness, and healthcare resource utilization (hcru) for patients diagnosed with primary small cell lung cancer sclc (extensive stage \& limited stage)and stage iii nsclc in a real-world setting.

a retrospective, multi-centre, observational study to describe the treatment patterns, the demographic, clinical outcomes, treatment effectiveness, and healthcare resource utilization (hcru) for patients diagnosed with primary small cell lung cancer sclc (extensive stage \& limited stage)and stage iii nsclc in a real-world setting cohort of patients diagnosed with primary sclc (limited or extensive stage) or stage iii nsclc, aims to characterize the treatment patterns from the index date (defined as the date of initial diagnosis of locally advanced stage iii nsclc and sclc) to the end of follow-up (defined as the earliest of death, last available medical record or end of the observation period "defined as the date of data abstraction") including the type of treatment received, duration of each treatment regimen, and reasons for stopping treatment regimen. the study population will be identified by participating physicians involved in the diagnosis, treatment and management of these patients through the review of established patient medical records. eligible patients (both alive and deceased) will have their data anonymously abstracted from their medical records into a centrally designed electronic case report form (ecrf).

Eligibility criteria:
inclusion criteria: * 1. adult male or female (≥18 years old or according to the age of majority as defined by local regulations). 2. first-ever diagnosis of lung cancer (absence of previous diagnosis of lung cancer, including sclc and nsclc) in the patient's medical records. 3. patients either diagnosed with a primary diagnosis of sclc (extensive or limited) or stage iii nsclc, confirmed by pathology, between 1st of january 2015 and 31st of december 2019. 4. medical records available at the participating site reflect at least nine months of follow-up from the index date (unless the patient died within the first nine months of diagnosis) exclusion criteria: * 1. patients with concomitant cancer at the time of diagnosis other than sclc or stage iii nsclc, except for non-metastatic non-melanoma skin cancers, or in situ or benign neoplasms. cancer will be considered concomitant if it occurs within five years of nsclc or sclc diagnosis 2. patients initially diagnosed with stage i to ii nsclc who have progressed to stage iii 3. current or prior use of "durvalumab" treatment

Keywords: small cell lung cancer (sclc) stage iii non-small cell lung cancer (nsclc)
sustained ketamine effectiveness for suicidal ideation

Conditions: Depression - Major Depressive Disorder; Suicide

Summary: as part of the usual clinical activity of the emergency and post-emergency psychiatric department, iv ketamine is used to treat suicidal crises in depressed patients hospitalized as an add-on to the treatment of depression. this infusion can be repeated. patients are systematically reassessed twice in the month following the last infusion, to ensure that the suicidal crisis is progressing. psychometric assessments are part of routine care, to ensure systematic evaluation of psychopathology, intensity of depression and suicidality. therefore existing data were re-used from the medical records of patients who had received ketamine infusions to assess the effect of ketamine on suicidal ideation and behaviour.


Eligibility criteria:
inclusion criteria: * patients treated with iv ketamine in the psychiatric emergency and post-emergency department (university hospital, montpellier) in context of suicidal crisis * over 18 y.o exclusion criteria: * opposition to data use * subject deprived of liberty (by judicial or administrative decision) * subject protected by law (guardianship or curatorship) * subject not affiliated to a social security system

Keywords: suicide depression major depressive disorder ketamine
cerebral oxygen, blood flow and ammonia uptake in patients with cirrhosis and an acute episode of hepatic encephalopathy (he)

Conditions: Liver Cirrhosis; Hepatic Encephalopathy

Summary: we wish to study patients with liver cirrhosis during and 2 weeks after an acute episode of liver coma (hepatic encephalopathy). by means of positron emission tomography we investigate; brain blood flow, brain ammonia uptake and brain oxygen consumption. we hypothesize that blood flow an oxygen consumption is diminished and ammonia uptake increased during an acute episode of hepatic encephalopathy.


Eligibility criteria:
inclusion criteria: * patients with an acute episode of hepatic encephalopathy exclusion criteria: * previous stroke

Keywords: liver cirrhosis hepatic encephalopathy ammonia cerebral blood flow